Edetate Disodium Anhydrous
drugOn this page
Also known as Anhydrous disodium edetateE386Edetate disodiumanhydrousEdetic aciddisodium saltEdta disodium salt anhydrousNSC-2760Disodium ethylenediaminetetraacetic acid
Summary
Edetate Disodium Anhydrous (CHEMBL1749) is an approved small-molecule chelator.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Chemistry: 336.21 Da · C10H14N2Na2O8
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1749 |
| Name | Edetate Disodium Anhydrous |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 8759 |
| ChEBI | CHEBI:64734 |
| Molecular formula | C10H14N2Na2O8 |
| Molecular weight | 336.21 |
| InChIKey | ZGTMUACCHSMWAC-UHFFFAOYSA-L |
SMILES: C(CN(CC(=O)O)CC(=O)[O-])N(CC(=O)O)CC(=O)[O-].[Na+].[Na+]
IUPAC name: disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate
ChEBI definition: An organic sodium salt that is the anhydrous form of the disodium salt of ethylenediaminetetraacetic acid (EDTA).
Pharmacological roles (ChEBI): chelator.
Also known as: Anhydrous disodium edetate, E386, Edetate disodium anhydrous, Edetate disodium, anhydrous, Edetic acid, disodium salt, Edta disodium salt anhydrous, NSC-2760, EDETATE DISODIUM ANHYDROUS, Disodium ethylenediaminetetraacetic acid
Parent form; salt/anhydrous children: CHEMBL3989507
Patent coverage: 78,424 distinct patent families (180,483 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 111,146 (62%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
0 indications (0 at ChEMBL trial phase 4).
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.